Pulmonary Artery Pseudoaneurysm: A Rare Cause of Fatal Massive Hemoptysis

Himaja Koneru1, Sreeja Biswas Roy2, Monirul Islam1

  • 1Department of Thoracic Medicine, Geisinger Medical Center, Danville, PA, USA.

Insights

Pulmonary artery pseudoaneurysms (PAPA) are rare, life-threatening infections of the pulmonary artery. Early diagnosis and endovascular treatment are crucial for managing this condition, especially in cases of hemoptysis.

Area of Science:

  • Cardiology
  • Pulmonary Medicine
  • Infectious Diseases

Background:

  • Pulmonary artery pseudoaneurysm (PAPA) is an uncommon but high-mortality complication of infections and septic emboli.
  • The pulmonary artery's lack of an adventitial wall predisposes it to rupture compared to systemic aneurysms.

Observation:

  • PAPA commonly presents as massive hemoptysis and hypoxemia.
  • Computed tomography angiography is the preferred diagnostic tool, revealing characteristic contrast-filled outpouchings.
  • Mycotic PAPAs often present with multiple lesions due to ongoing embolic phenomena.

Findings:

  • The case highlights a fatal outcome from a ruptured PAPA in a young woman with necrotizing pneumonia secondary to intravenous drug use.
  • Endovascular treatment is preferred for hemoptysis, while prolonged antimicrobial therapy is recommended for mycotic PAPA.
  • Surgical resection is a last resort for refractory cases.

Implications:

  • This case underscores the critical need for prompt diagnosis and management of PAPA.
  • Effective treatment strategies, including endovascular interventions, can improve patient outcomes.
  • Understanding the pathophysiology is vital for preventing rupture and mortality in patients with PAPA.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
619
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
479
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
513
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
633
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
553
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
998